130 related articles for article (PubMed ID: 31667887)
21. Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation.
Ottaviano G; Chiesa R; Feuchtinger T; Vickers MA; Dickinson A; Gennery AR; Veys P; Todryk S
Cells; 2019 Jan; 8(1):. PubMed ID: 30646564
[TBL] [Abstract][Full Text] [Related]
22. Applications of virus-specific T cell therapies post-BMT.
Motta CM; Keller MD; Bollard CM
Semin Hematol; 2023 Jan; 60(1):10-19. PubMed ID: 37080705
[TBL] [Abstract][Full Text] [Related]
23. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
24. Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.
Qian C; Wang Y; Reppel L; D'aveni M; Campidelli A; Decot V; Bensoussan D
Bone Marrow Transplant; 2018 Feb; 53(2):114-122. PubMed ID: 29058697
[TBL] [Abstract][Full Text] [Related]
25. Virus-specific T-cell therapies for patients with primary immune deficiency.
Keller MD; Bollard CM
Blood; 2020 Feb; 135(9):620-628. PubMed ID: 31942610
[TBL] [Abstract][Full Text] [Related]
26. Virus-Specific T Cells for the Immunocompromised Patient.
Houghtelin A; Bollard CM
Front Immunol; 2017; 8():1272. PubMed ID: 29075259
[TBL] [Abstract][Full Text] [Related]
27. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection.
Qian C; Wang Y; Cai H; Laroye C; De Carvalho Bittencourt M; Clement L; Stoltz JF; Decot V; Reppel L; Bensoussan D
J Immunother; 2016 Jan; 39(1):27-35. PubMed ID: 26641259
[TBL] [Abstract][Full Text] [Related]
29. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
30. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.
Papadopoulou A; Gerdemann U; Katari UL; Tzannou I; Liu H; Martinez C; Leung K; Carrum G; Gee AP; Vera JF; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
Sci Transl Med; 2014 Jun; 6(242):242ra83. PubMed ID: 24964991
[TBL] [Abstract][Full Text] [Related]
31. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.
Withers B; Blyth E; Clancy LE; Yong A; Fraser C; Burgess J; Simms R; Brown R; Kliman D; Dubosq MC; Bishop D; Sutrave G; Ma CKK; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood Adv; 2017 Nov; 1(24):2193-2205. PubMed ID: 29296867
[TBL] [Abstract][Full Text] [Related]
32. Failure of Viral-Specific T Cells Administered in Pre-transplant Settings in Children with Inborn Errors of Immunity.
Alonso L; Méndez-Echevarría A; Rudilla F; Mozo Y; Soler-Palacin P; Sisinni L; Bueno D; Riviere J; de Paz R; Sánchez-Zapardiel E; Querol S; Rodriguez-Pena R; López-Granados E; Gimeno R; Díaz de Heredia C; Pérez-Martínez A
J Clin Immunol; 2021 May; 41(4):748-755. PubMed ID: 33462728
[TBL] [Abstract][Full Text] [Related]
33. A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.
Li Pira G; Ivaldi F; Starc N; Landi F; Rutella S; Locatelli F; Sacchi N; Tripodi G; Manca F
Transfusion; 2014 Dec; 54(12):3145-54. PubMed ID: 25041366
[TBL] [Abstract][Full Text] [Related]
34. Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation.
Green A; Rubinstein JD; Grimley M; Pfeiffer T
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S49-S57. PubMed ID: 38417086
[TBL] [Abstract][Full Text] [Related]
35. Ultra-Sensitive Droplet Digital PCR for the Assessment of Microchimerism in Cellular Therapies.
Kliman D; Castellano-Gonzalez G; Withers B; Street J; Tegg E; Mirochnik O; Lai J; Clancy L; Gottlieb D; Blyth E
Biol Blood Marrow Transplant; 2018 May; 24(5):1069-1078. PubMed ID: 29305193
[TBL] [Abstract][Full Text] [Related]
36. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors.
Steininger PA; Strasser EF; Weiss D; Achenbach S; Zimmermann R; Eckstein R
Vox Sang; 2014 Apr; 106(3):248-55. PubMed ID: 24152115
[TBL] [Abstract][Full Text] [Related]
37. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.
Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H
Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314
[TBL] [Abstract][Full Text] [Related]
38. Generation of good manufacturing practice grade virus-specific T cells for the management of post-transplant CMV infections.
Arunachalam AK; Palani HK; Yasar M; Kulkarni U; Mathews V; George B
J Immunol Methods; 2022 Dec; 511():113375. PubMed ID: 36243107
[TBL] [Abstract][Full Text] [Related]
39. Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System.
Kumaresan P; Figliola M; Moyes JS; Huls MH; Tewari P; Shpall EJ; Champlin R; Cooper LJ
J Vis Exp; 2015 Oct; (104):. PubMed ID: 26484782
[TBL] [Abstract][Full Text] [Related]
40. Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells.
McGuire HM; Rizzetto S; Withers BP; Clancy LE; Avdic S; Stern L; Patrick E; Fazekas de St Groth B; Slobedman B; Gottlieb DJ; Luciani F; Blyth E
Clin Transl Immunology; 2020; 9(7):e1149. PubMed ID: 32642063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
